Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.23)
# 2,755
Out of 5,157 analysts
75
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Hold | $22 → $20 | $22.10 | -9.48% | 17 | May 8, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $29.88 | -49.80% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $14.61 | -45.24% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $25.54 | +95.77% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $129.81 | +4.77% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $6.98 | +129.23% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $9.67 | +541.16% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $2.35 | +411.73% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $17.14 | +535.94% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $3.31 | +141.69% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.01 | +149.38% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.55 | +1,069.59% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $24.54 | -75.55% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.00 | +200.00% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $139.60 | -83.52% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $65.20 | -44.78% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
May 8, 2025
Maintains: Hold
Price Target: $22 → $20
Current: $22.10
Upside: -9.48%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $29.88
Upside: -49.80%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $14.61
Upside: -45.24%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $25.54
Upside: +95.77%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $129.81
Upside: +4.77%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $6.98
Upside: +129.23%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $9.67
Upside: +541.16%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $2.35
Upside: +411.73%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $17.14
Upside: +535.94%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $3.31
Upside: +141.69%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.01
Upside: +149.38%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $8.55
Upside: +1,069.59%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $24.54
Upside: -75.55%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $7.00
Upside: +200.00%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $139.60
Upside: -83.52%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $65.20
Upside: -44.78%